The Add-Aspirin trial is for people who have had, or have started treatment for, cancer of the breast, stomach, oesophagus (food pipe), prostate or bowel (see Who can take part?)
We are aiming to find out whether taking aspirin daily for 5 years after treatment for an early stage cancer (cancer that has not spread widely) stops or delays the cancer coming back. This study will compare groups of people who take aspirin and those who take placebo tablets (see What is a placebo?).
This trial is randomised (see What are randomised controlled trials?). This means that people taking part are put into the treatment groups at random by a computer. Neither the participant nor their doctor will know or be able to decide whether the participant is taking aspirin or a placebo.
For more information on the trial treatment, visit Treatment in the Add-Aspirin Trial webpage, and see the Participant Information Video below.
This video is approved for UK use only.
This video has received ethical approval in the UK.
Clarifications:
Contact Details
If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.
For healthcare professionals
Please log into the members area for Add-Aspirin contact details.
Register Interest
For healthcare professionals
If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk
From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.
To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.
Unblind a participant in the UK